Vivos Therapeutics VVOS 深 沪
已收盘 12-19 16:00:00 美东时间
1.97
-0.010
-0.51%
华盛通- 最 高2.0692
- 今 开2.00
- 成交量 8.42万股
- 最 低 1.97
- 昨 收 1.98
- 总市值 1478.45万
- 52周最高 7.95
- 市盈率 静 --
- 换手率 1.12%
- 52周最低 1.925
- 委 比 44.38%
- 总股本 750.48万
- 历史最高 360.25
- 量 比 0.55
- 振 幅 5.01%
- 历史最低 1.91
- 每 手 1
- 风险率 1.10%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Vivos Therapeutics to Participate in Online Fireside Chat with Water Tower Research on December 16, 2025, at 11 am EST
Vivos Therapeutics, Inc. (NASDAQ: VVOS) announced that CEO Kirk Huntsman and CFO Brad Amman will participate in a fireside chat on December 16, 2025, at 11:00 am ET with Robert Sassoon of Water Tower Research. The discussion will cover Vivos' strategic business model pivot, operational execution, market opportunity, competitive environment, growth, and financial strategies. The event is listen-only and available for registration at www.globenewsw...
12-15 22:30
Vivos Therapeutics Secures $2M Note with Avondale
Vivos Therapeutics ( ($VVOS) ) has provided an announcement. On December 5, 202...
12-06 06:28
美股大行评级 | 美鹰服饰、CrowdStrike、迈威尔科技获多家机构上调目标价；ACHC、GitLab、Okta遭多家机构下调目标价
今日重点评级关注：Guggenheim：维持Cybin Inc. Common Shares"买入"评级，目标价从39美元升至48美元；HC Wainwright & Co.：维持Capricor Therapeutics"买入"评级，目标价从24美元升至60美元
12-04 09:38
Ascendiant Capital Maintains Buy on Vivos Therapeutics, Lowers Price Target to $5.5
Ascendiant Capital analyst Lucas Ward maintains Vivos Therapeutics (NASDAQ:VVOS) with a Buy and lowers the price target from $6.5 to $5.5.
12-03 19:47
Vivos Therapeutics Q3 EPS $(0.49) Misses $(0.41) Estimate, Sales $6.783M Beat $4.686M Estimate
Vivos Therapeutics (NASDAQ:VVOS) reported quarterly losses of $(0.49) per share which missed the analyst consensus estimate of $(0.41) by 18.07 percent. This is a 22.5 percent decrease over losses of $(0.40) per share
11-20 05:08
美股大行评级 | Stifel上调特斯拉目标价升至508美元；多家大行上调Vita Coco目标价最高至58美元
今日重点评级关注：HC Wainwright & Co.：维持Oncolytics Biotech"买入"评级，目标价从5美元升至10美元；HC Wainwright & Co.：维持Barinthus Biotherapeutics"买入"评级，目标价从3美元升至4美元
11-18 15:28
HC Wainwright & Co. Initiates Coverage On Vivos Therapeutics with Buy Rating, Announces Price Target of $7
HC Wainwright & Co. analyst Yi Chen initiates coverage on Vivos Therapeutics (NASDAQ:VVOS) with a Buy rating and announces Price Target of $7.
11-17 20:31
Vivos Therapeutics Delays Q3 Report Amid Acquisition
Vivos Therapeutics ( ($VVOS) ) has released a notification of late filing. Vivo...
11-15 05:54
Vivos' Study Demonstrates Its Daytime-Nighttime Appliance Provides Relief, Quality Of Life Improvement In Children With Attention-Deficit/Hyperactivity Disorder, Obstructive Sleep Apnea
Previously Unpublished Data Confirms Vivos DNA Devices Offer a Safe and Effective Alternative Treatment for Children with ADHD and Obstructive Sleep Apnea LITTLETON, Colo., Sept. 30, 2025 (GLOBE NEWSWIRE) -- Vivos
09-30 20:41
Vivos Therapeutics Releases Additional Clinical Data Showing Marked Improvement in Pediatric ADHD from Use of Vivos DNA Device
Vivos Therapeutics发布新数据显示，其FDA认证的DNA设备能有效缓解儿童ADHD和阻塞性睡眠呼吸暂停（OSA）症状。该设备是非手术、非药物治疗中重度OSA的创新方案，临床试验显示患儿症状改善显著。
09-30 12:30
